3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
1
Phase 1
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Conditions
Melanoma
10
Urinary Bladder Neoplasms
3
Stomach Neoplasms
3
Neoplasms
3
Colorectal Neoplasms
3
Colonic Neoplasms
3
Uveal Melanoma
2
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Rectal Neoplasms
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Lymphoma
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Carcinoma, Basal Cell
2
Advanced Cancer
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Turcot syndrome
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Spinocerebellar Degenerations
1
Sarcoma
1
Interventions
relatlimab
2
linrodostat
2
Nivolumab
2
Ipilimumab
2
Vorinostat
1
Trastuzumab
1
IFL protocol
1
Gemcitabine
1
Dasatinib
1
Cetuximab
1
BMS-813160
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Advanced Cancer
×
relatlimab
×
Clear all
NCT02996110
2022-12-19
FRACTION-RCC
Bristol-Myers Squibb
Phase 2
Completed
182 enrolled
23 charts
NCT02750514
2021-03-22
FRACTION-Lung
Bristol-Myers Squibb
Phase 2
Terminated
295 enrolled
21 charts